![](/img/cover-not-exists.png)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)
Garcia-Carbonero, R., Van Cutsem, E., Ciardiello, F., Ychou, M., Seitz, J-F., Hofheinz, R.D., Arriaga, Y., Verma, U., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw370.54
Date:
October, 2016
File:
PDF, 46 KB
english, 2016